Literature DB >> 2526305

Evidence for a dopaminergic innervation of cat primary visual cortex.

D Parkinson1.   

Abstract

Experiments have been conducted to determine whether dopamine fulfills the criteria to be considered as a neurotransmitter in cat primary visual cortex. N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine, a neurotoxin with high selectivity for noradrenergic terminals, was administered into kitten cerebral ventricles. Two weeks later, the concentration of norepinephrine in visual cortex was reduced to 15% of control while dopamine and serotonin were not depleted. Receptor binding assays with [3H]SCH 23390 showed that membranes prepared from cat primary visual cortex contain a binding site that has the properties of a D1 receptor. This site was localized by autoradiography to two bands, one in layer VI and the second in upper layers of visual cortex. A dopamine-stimulated adenylate cyclase activity was demonstrated that was inhibited by SCH 23390 but not by alprenolol. Norepinephrine was shown to stimulate adenylate cyclase activity through both a beta-noradrenergic receptor and a D1 receptor. Binding assays with [3H]spiperone indicated that D2 dopamine receptors are absent from cat visual cortex or present in very low amounts. Taken together these results strongly suggest the existence of a dopamine innervation of cat primary visual cortex. The neurotoxin experiments show that some of the dopamine in cat visual cortex is not in noradrenergic terminals while the receptor assays demonstrate the presence of D1 receptors functionally linked to the synthesis of cyclic 3',5'-adenosine monophosphate. The demonstration of a dopaminergic innervation in cat primary visual cortex is also relevant to the interpretation of data on the involvement of catecholamines in developmental plastic phenomena.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526305     DOI: 10.1016/0306-4522(89)90363-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  8 in total

1.  Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease.

Authors:  Ozgül Altintaş; Pervin Işeri; Berna Ozkan; Yusuf Cağlar
Journal:  Doc Ophthalmol       Date:  2007-10-26       Impact factor: 2.379

2.  Visual and cognitive predictors of driving safety in Parkinson's disease patients.

Authors:  M M Amick; J Grace; B R Ott
Journal:  Arch Clin Neuropsychol       Date:  2007-09-11       Impact factor: 2.813

3.  Retinal dysfunction of contrast processing in major depression also apparent in cortical activity.

Authors:  Emanuel Bubl; Elena Kern; Dieter Ebert; Andreas Riedel; Ludger Tebartz van Elst; Michael Bach
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-01-08       Impact factor: 5.270

4.  Sound sequence discrimination learning motivated by reward requires dopaminergic D2 receptor activation in the rat auditory cortex.

Authors:  Masaharu Kudoh; Katsuei Shibuki
Journal:  Learn Mem       Date:  2006 Nov-Dec       Impact factor: 2.460

5.  Sensitization to apomorphine in pigeons: unaffected by latent inhibition but still due to classical conditioning.

Authors:  B Wynne; J D Delius
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

6.  Hyperstimulation of striatal D2 receptors with sleep deprivation: Implications for cognitive impairment.

Authors:  Nora D Volkow; Dardo Tomasi; Gene-Jack Wang; Frank Telang; Joanna S Fowler; Ruiliang L Wang; Jean Logan; Christopher Wong; Millard Jayne; James M Swanson
Journal:  Neuroimage       Date:  2009-01-20       Impact factor: 6.556

7.  Cognitive functions and stereopsis in patients with Parkinson's disease and Alzheimer's disease using 3-dimensional television: a case controlled trial.

Authors:  Chan-Nyoung Lee; Deokwon Ko; Young-Woo Suh; Kun-Woo Park
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

8.  Optical Coherence Tomography Findings in Parkinson's and Alzheimer's Disease -Retinal Changes in Neurodegenerative Disease.

Authors:  Derya Bayram; Gülbün Yüksel; Tamer Bayram; Hülya Tireli
Journal:  Noro Psikiyatr Ars       Date:  2019-08-26       Impact factor: 1.339

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.